Study of Irinotecan and Cisplatin with Radiotherapy for Lung Cancer
Author Information
Author(s): A Yokoyama, Y Kurita, N Saijo, T Tamura, K Noda, K Shimokata, T Matsuda
Primary Institution: Niigata Cancer Center Hospital
Hypothesis
Can irinotecan and cisplatin combined with radiotherapy improve outcomes for patients with unresectable stage III non-small-cell lung cancer?
Conclusion
The combination of irinotecan and cisplatin with concurrent radiotherapy was found to be unacceptable due to high toxicity and low treatment completion rates.
Supporting Evidence
- Four of six patients at level 1 completed the treatment.
- An overall response rate of 67% was observed.
- Leucopenia was the principal myelotoxic adverse effect.
Takeaway
Doctors wanted to see if a new cancer treatment could help patients with a tough type of lung cancer, but it turned out to be too hard on their bodies.
Methodology
Patients received three courses of chemotherapy with irinotecan and cisplatin, followed by radiation therapy over six weeks.
Limitations
The study was discontinued due to unacceptable toxicity and low dose intensity.
Participant Demographics
{"age":{"median":58,"range":"35-68"},"sex":{"male":9,"female":3},"performance_status":{"0":3,"1":9},"cell_type":{"adenocarcinoma":7,"squamous":4,"large_cell":1},"clinical_stage":{"IIIA":2,"IIIB":10}}
Want to read the original?
Access the complete publication on the publisher's website